The Association of Area Deprivation and State Child Health with Respiratory Outcomes of Pediatric Patients with Cystic Fibrosis in the United States
Multivariate joint modeling to identify markers of growth and lung function decline that predict cystic fibrosis pulmonary exacerbation onset
Tobacco Smoke Exposure Limits the Therapeutic Benefit of Tezacaftor-Ivacaftor in Pediatric Patients with Cystic Fibrosis.
Long-term health effects of real-world use of ivacaftor by people with cystic fibrosis who have non-G551D-CFTR gating mutations
Adjusting the dose of triple therapy (Elexacaftor/Tezacaftor/Ivacaftor) to reduce mental health side effects
How ivacaftor changes inflammation and protein levels in the bloodstream of people with CF and the G551D mutation
How the number of kinds of antibiotics chosen to treat Pseudomonas during an exacerbation affect recovery
